Auris Medical Holding Ltd. (NASDAQ: EARS) jumped 8.74% after the company announced promising results from an in vivo trial showing considerable tumor growth inhibition by siRNA NF-kB knockdown using its OligoPhore tech in Adult T-cell Leukemia-Lymphoma (ATLL). The company published the results in an international peer-reviewed journal, Nanomaterials.
Researchers tested RNA nanoparticles.
Research teams from Washington University in St. Louis, Missouri, and the University of South Florida in Tampa, Florida, collaborated on the study. The researchers created and tested RNA nanoparticles using Auris Medical’s OligoPhoreTM peptide carrier with siRNA to target two NF-B signaling pathways simultaneously. The NF-B protein complex regulates the immunological resistance to infection and is vital for the growth of ATLL tumors. The researchers gave siRNA nanoparticles to two sets of mice, one with spontaneous ATLL tumor growth and the other with tumor cell transplantation.
The study found that siRNA delivered to the tumor quickly and reduced target mRNA and protein expression significantly, altering the natural history of future tumor progression. Treated mice had considerably smaller tumors, spleens, and peripheral blood lymphocyte counts than controls (p0.01), and tumor development was decreased to close to zero in the most aggressive tumors. Furthermore, the siRNA nanoparticles made late-stage ATLL tumors more susceptible to etoposide treatment.
The study yields promising results.
Auris Medical Chief Scientific Officer Samuel Wickline said that the investigation with ATLL mice yielded very promising results, which are promising. He stated that ATLL is a complex disease with a high fatality rate. Although NF-B has been identified as a viable target for some time, it has so far eluded precise and successful treatment. Wickline added that because ATLL is a highly malignant tumor without a targeted molecular therapy, the finding encourages drug discovery and development in this therapeutic indication and for other tumors and inflammatory pathological conditions involving the NF-B molecular target.